Integral Diagnostics Past Earnings Performance
Past criteria checks 0/6
Integral Diagnostics's earnings have been declining at an average annual rate of -47.6%, while the Healthcare industry saw earnings declining at 3.3% annually. Revenues have been growing at an average rate of 13.8% per year.
Key information
-47.6%
Earnings growth rate
-48.7%
EPS growth rate
| Healthcare Industry Growth | 2.4% |
| Revenue growth rate | 13.8% |
| Return on equity | -20.1% |
| Net Margin | -12.9% |
| Next Earnings Update | 25 Feb 2025 |
Recent past performance updates
Recent updates
Some Investors May Be Worried About Integral Diagnostics' (ASX:IDX) Returns On Capital
Feb 21
Shareholders Will Probably Hold Off On Increasing Integral Diagnostics Limited's (ASX:IDX) CEO Compensation For The Time Being
Nov 22Integral Diagnostics' (ASX:IDX) Shareholders Will Receive A Smaller Dividend Than Last Year
Feb 20These 4 Measures Indicate That Integral Diagnostics (ASX:IDX) Is Using Debt Extensively
Dec 14Should You Think About Buying Integral Diagnostics Limited (ASX:IDX) Now?
May 26Integral Diagnostics (ASX:IDX) Is Paying Out Less In Dividends Than Last Year
Feb 28Integral Diagnostics Limited (ASX:IDX) Shares Could Be 38% Below Their Intrinsic Value Estimate
Feb 25Shareholders Would Not Be Objecting To Integral Diagnostics Limited's (ASX:IDX) CEO Compensation And Here's Why
Oct 29Does Integral Diagnostics (ASX:IDX) Deserve A Spot On Your Watchlist?
Sep 13An Intrinsic Calculation For Integral Diagnostics Limited (ASX:IDX) Suggests It's 22% Undervalued
Jun 04Should You Be Adding Integral Diagnostics (ASX:IDX) To Your Watchlist Today?
May 14Is Integral Diagnostics Limited (ASX:IDX) A Smart Choice For Dividend Investors?
May 03We Think Integral Diagnostics (ASX:IDX) Can Stay On Top Of Its Debt
Apr 16Is It Too Late To Consider Buying Integral Diagnostics Limited (ASX:IDX)?
Mar 27Is Integral Diagnostics Limited's (ASX:IDX) Stock's Recent Performance A Reflection Of Its Financial Health?
Mar 17The Trends At Integral Diagnostics (ASX:IDX) That You Should Know About
Mar 07Here's What We Like About Integral Diagnostics' (ASX:IDX) Upcoming Dividend
Feb 25Is Integral Diagnostics Limited (ASX:IDX) Popular Amongst Institutions?
Feb 23Have Insiders Been Selling Integral Diagnostics Limited (ASX:IDX) Shares?
Feb 13Integral Diagnostics Limited's (ASX:IDX) Intrinsic Value Is Potentially 46% Above Its Share Price
Feb 03
Here's What We Learned About The CEO Pay At Integral Diagnostics Limited (ASX:IDX)
Jan 24Should You Use Integral Diagnostics's (ASX:IDX) Statutory Earnings To Analyse It?
Jan 14Shareholders Of Integral Diagnostics (ASX:IDX) Must Be Happy With Their 201% Total Return
Jan 05Is Integral Diagnostics (ASX:IDX) A Risky Investment?
Dec 26At AU$4.30, Is It Time To Put Integral Diagnostics Limited (ASX:IDX) On Your Watch List?
Dec 17What To Know Before Buying Integral Diagnostics Limited (ASX:IDX) For Its Dividend
Dec 08Revenue & Expenses Breakdown
How Integral Diagnostics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 470 | -61 | 27 | 15 |
| 31 Mar 24 | 463 | -59 | 26 | 14 |
| 31 Dec 23 | 456 | -58 | 26 | 0 |
| 30 Sep 23 | 449 | -16 | 26 | 0 |
| 30 Jun 23 | 441 | 25 | 25 | 13 |
| 31 Mar 23 | 418 | 23 | 24 | 6 |
| 31 Dec 22 | 395 | 21 | 22 | 0 |
| 30 Sep 22 | 378 | 18 | 21 | 0 |
| 30 Jun 22 | 361 | 15 | 21 | 0 |
| 31 Mar 22 | 361 | 18 | 21 | 0 |
| 31 Dec 21 | 360 | 22 | 22 | 0 |
| 30 Sep 21 | 356 | 26 | 22 | 0 |
| 30 Jun 21 | 351 | 31 | 22 | 0 |
| 31 Mar 21 | 333 | 32 | 21 | 0 |
| 31 Dec 20 | 315 | 32 | 19 | 0 |
| 30 Sep 20 | 295 | 28 | 18 | 0 |
| 30 Jun 20 | 276 | 23 | 16 | 0 |
| 31 Mar 20 | 263 | 22 | 18 | 0 |
| 31 Dec 19 | 250 | 21 | 19 | 0 |
| 30 Sep 19 | 241 | 21 | 21 | 0 |
| 30 Jun 19 | 232 | 21 | 24 | 0 |
| 31 Mar 19 | 222 | 19 | 23 | 0 |
| 31 Dec 18 | 211 | 17 | 23 | 0 |
| 30 Sep 18 | 200 | 16 | 22 | 0 |
| 30 Jun 18 | 189 | 15 | 21 | 0 |
| 31 Mar 18 | 187 | 15 | 21 | 0 |
| 31 Dec 17 | 185 | 15 | 20 | 0 |
| 30 Sep 17 | 182 | 15 | 20 | 0 |
| 30 Jun 17 | 180 | 15 | 20 | 0 |
| 31 Mar 17 | 177 | 16 | 19 | 0 |
| 31 Dec 16 | 175 | 16 | 19 | 0 |
| 30 Sep 16 | 171 | 14 | 18 | 0 |
| 30 Jun 16 | 168 | 11 | 18 | 0 |
| 31 Mar 16 | 165 | 11 | 17 | 0 |
| 31 Dec 15 | 162 | 11 | 17 | 0 |
| 30 Sep 15 | 157 | 8 | 17 | 0 |
| 30 Jun 15 | 151 | 5 | 16 | 0 |
| 30 Jun 14 | 4 | 3 | 1 | 0 |
Quality Earnings: IDX is currently unprofitable.
Growing Profit Margin: IDX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IDX is unprofitable, and losses have increased over the past 5 years at a rate of 47.6% per year.
Accelerating Growth: Unable to compare IDX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IDX is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-25.4%).
Return on Equity
High ROE: IDX has a negative Return on Equity (-20.12%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/23 07:37 |
| End of Day Share Price | 2025/01/23 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Integral Diagnostics Limited is covered by 23 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Benjamin Brayshaw | Barrenjoey Markets Pty Limited |
| Thomas Yeo | Barrenjoey Markets Pty Limited |
| Saul Hadassin | Barrenjoey Markets Pty Limited |